Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Postmortem Analysis in a Clinical Trial of AAV2-NGF Gene Therapy for Alzheimer's Disease Identifies a Need for Improved Vector Delivery.

Castle MJ, Baltanás FC, Kovacs I, Nagahara AH, Barba D, Tuszynski MH.

Hum Gene Ther. 2020 Mar 4. doi: 10.1089/hum.2019.367. [Epub ahead of print]


In Situ Hybridization for Detection of AAV-Mediated Gene Expression.

Hunter JE, Gurda BL, Yoon SY, Castle MJ, Wolfe JH.

Methods Mol Biol. 2019;1950:107-122. doi: 10.1007/978-1-4939-9139-6_6.


Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion.

Castle MJ, Cheng Y, Asokan A, Tuszynski MH.

Sci Adv. 2018 Nov 14;4(11):eaau9859. doi: 10.1126/sciadv.aau9859. eCollection 2018 Nov.


Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Castle MJ, Turunen HT, Vandenberghe LH, Wolfe JH.

Methods Mol Biol. 2016;1382:133-49. doi: 10.1007/978-1-4939-3271-9_10.


Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport.

Castle MJ, Gershenson ZT, Giles AR, Holzbaur EL, Wolfe JH.

Hum Gene Ther. 2014 Aug;25(8):705-20. doi: 10.1089/hum.2013.189. Epub 2014 May 2.


Long-distance axonal transport of AAV9 is driven by dynein and kinesin-2 and is trafficked in a highly motile Rab7-positive compartment.

Castle MJ, Perlson E, Holzbaur EL, Wolfe JH.

Mol Ther. 2014 Mar;22(3):554-566. doi: 10.1038/mt.2013.237. Epub 2013 Oct 8.


Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey.

Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R, Wang L, Castle MJ, Maguire AC, Grant R, Wolfe JH, Wilson JM, Bennett J.

Sci Transl Med. 2011 Jun 22;3(88):88ra54. doi: 10.1126/scitranslmed.3002103. Erratum in: Sci Transl Med. 2011 Dec 7;3(112):112er9.

Supplemental Content

Loading ...
Support Center